Tagrisso (osimertinib)

pCPA File Number: 21713

Negotiation Status:

Concluded with an LOI

Indication(s):

Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CADTH Project Number:

PC0246

pCPA Engagement Letter Issued:

2022-05-16

Negotiation Process Concluded:

2022-10-07